¨O vitiligo se caracteriza por manchas acrômicas relacionadas à perda de melanócitos da epiderme e folículo piloso, em qualquer área da pele, que não têm melanócitos. Incide em qualquer idade, em ambos os sexos e acomete até 2% da população em algumas regiões. Vitiligo é um transtorno de pigmentação freqüente na população mundial. Alguns fatores precipitantes para essa doença são: estresse físico e emocional, traumas mecânicos e substâncias químicas, como derivados do fenol. Doenças auto-imunes, principalmente as tireoidianas, podem estar associadas ao vitiligo. O vitiligo é dermatose de difícil tratamento e de significativo impacto psicossocial. Seu tratamento ainda oferece resultados limitados em alguns pacientes. Novas terapias têm sido propostas, como o uso de imunomoduladores tópicos, aliadas àquelas já consolidadas, como os psoralenos e os corticosteróides; o sucesso terapêutico, entretanto, está estritamente relacionado à qualidade da relação médico/paciente. Nos casos de vitiligo estável clinicamente, o transplante de melanócitos torna se uma opção terapêutica, sendo a técnica de enxertos autólogos por punch empregada com boa resposta na repigmentação. ¨
■ Clinical and molecular aspects of vitiligo treatments
Anuradha Bishnoi, Davinder Parsad
Int J Mol Sci. 2018 May; 19(5): 1509
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983813/
■ Vitiligo: patients stories, self-esteem, and the psychological burden of disease
P.E. Grimes, M.M. Miller
Int J Womens Dermatol. 2018 Mar; 4(1): 32–37
www.ncbi.nlm.nih.gov/pmc/articles/PMC5986114/
■ A case series pilot study on the combination of 5-aminolevulinic acid and photodynamic therapy (ALA-PDT) for treatment of vitiligo.
Zhang, YunJie et al.
An. Bras. Dermatol., Aug 2018, vol.93, no.4, p.539-545
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962018000400008&lng=en&nrm=iso
■ Macrophage migration inhibitory factor as an incriminating agent in vitiligo
Farag, Azza Gaber Antar et al.
An. Bras. Dermatol., Mar 2018, vol.93, no.2, p.191-196
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S036
05962018000200191&lng=en&nrm=iso
■ Vitiligo appearing after oral isotretinoin therapy for acne
A A Kokandi
Case Reports in Dermatological Medicine 2018, Article ID 3697260, 3 pages
https://www.hindawi.com/journals/cridm/2018/3697260/
■ Vitiligo patients show significant up-regulation of aryl hydrocarbon receptor transcription factor
Behfarjam, Farinaze and Jadali, Zohreh
An. Bras. Dermatol., Mar 2018, vol.93, no.2, p.302-303
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962018000200302&lng=en&nrm=iso
■ A study of the association of glutathione S-transferase M1/T1 polymorphisms with susceptibility to vitiligo in Egyptian patients
Aly, Dalia Gamal et al.
An. Bras. Dermatol., Feb 2018, vol.93, no.1, p.54-58
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962018000100054&lng=en&nrm=iso
■ Phototherapy for vitiligo: a systematic review and meta-analysis
Jung Min Bae, Han Mi Jung, Bo Young Hong et al
JAMA Dermatol. 2017 Jul; 153(7): 666–674
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817459/
■ Advances in vitiligo: an update on medical and surgical treatments
Alexander B. Dillon, Andrew Sideris, Ali Hadi, Nada Elbuluk
J Clin Aesthet Dermatol. 2017 Jan; 10(1): 15–28
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300730/
■ Vitiligo pathogenesis and emerging treatments
Mehdi Rashighi, John E. Harris
Dermatol Clin. 2017 Apr; 35(2): 257–265
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362109/
■ Adult onset vitiligo: multivariate analysis suggest the need for a thyroid screening
- Lazzeri, R. Colucci, A. Cammi, F. Dragoni, S. Moretti
Biomed Res Int. 2016; 2016: 806576
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055927/
■ Anemia perniciosa en una paciente con artritis reumatoide y vitiligo
Rivas-de Noriega, JP, Ontañon-Zurita, D and Turrent-Carriles, A
Med. interna Méx., Ago 2017, vol.33, no.4, p.522-525
http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0186-48662017000400522&lng=es&nrm=iso
■ Prevalence and clinical characteristics of itch in vitiligo and its clinical significance
Vasanop Vachiramon, Woranit Onprasert, Sarawin Harnchoowong, Kumutnart Chanprapaph
Biomed Res Int. 2017; 2017: 5617838
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554571/
■ Vitiligo and autoimmune thyroid disorders
Enke Baldini, Teresa Odorisio, Salvatore Sorrenti et al
Front Endocrinol (Lausanne) 2017; 8: 29
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663726/
■ Optimizing suction blister epidermal graft technique in the surgical treatment of vitiligo
Dellatorre, Gerson, Bertolini, Wagner and Castro, Caio Cesar Silva de
An. Bras. Dermatol., Dec 2017, vol.92, no.6, p.888-890
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962017000600888&lng=en&nrm=iso
■ Insight into natural history of congenital vitiligo: a case report of a 23-year-old with stable congenital vitiligo
C Casey, S E Weis
Case Reports in Dermatological Medicine 2017, Article ID 5172140, 3 pages
https://www.hindawi.com/journals/cridm/2017/5172140/
■ Chemical-induced vitiligo
John E. Harris
Dermatol Clin. 2017 Apr; 35(2): 151–161
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362111/
■ Prepubertal and postpubertal vitiligo: a multivariate comparative study in 375 patients
Khurrum, Huma and AlGhamdi, Khalid M
An. Bras. Dermatol., Dec 2017, vol.92, no.6, p.811-815
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962017000600811&lng=en&nrm=iso
■ Evaluation of treatment response to autologous transplantation of noncultured melanocyte/keratinocyte cell suspension in patients with stable vitiligo
Ramos, Mariana Gontijo, Ramos, Daniel Gontijo and Ramos, Camila Gontijo
An. Bras. Dermatol., June 2017, vol.92, no.3, p.312-318
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962017000300312&lng=en&nrm=iso
■ Vitiligo blood transcriptomics provides new insigts into disease mechanisms and identifies potential novel therapeutic targets
Rama Dey-Rao, Animesh A. Sinha
BMC Genomics. 2017; 18: 109
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5273810/
■ Trends in regenerative medicine: repigmentation in vitiligo through melanocyte stem cell mobilization
Stanca A. Birlea, Gertrude-E. Costin, Dennis R. Roop, David A. Norris
Med Res Rev. 2017 Jul; 37(4): 907–93
https://www.ncbi.nlm.nih.gov/pmc/ticles/PMC5466503/
■ Increased risk of metabolic syndrome in patients with vitiligo
Hatice Ataş, Müzeyyen Gönül
Balkan Med J. 2017 May; 34(3): 219–225.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450861/
■ Knowledge, beliefs, and perceptions of Turkish vitiligo patients regarding their condition
Topal, Ilteris Oguz et al.
An. Bras. Dermatol., Dec 2016, vol.91, no.6, p.770-775
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600770&lng=en&nrm=iso
■ Understanding mechanisms of autoimmunity through translational research in vitiligo
James P Strassner, John E Harris
Curr Opin Immunol. 2016 Dec; 43: 81–88
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292941/
■ Nail abnormalities in patients with vitiligo
Topal, Ilteris Oguz et al.
An. Bras. Dermatol., Aug 2016, vol.91, no.4, p.442-445
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000400442&lng=en&nrm=iso
■ Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review.
Sisti, Andrea, Sisti, Giovanni and Oranges, Carlo Maria
An. Bras. Dermatol., Apr 2016, vol.91, no.2, p.187-195
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000200187&lng=en&nrm=iso
■ Understanding autoimmunity of vitiligo and alopecia areata
Jillian F. Rork, Mehdi Rashighi, John E. Harris
Curr Opin Pediatr. 2016 Aug; 28(4): 463–46
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957563/
■ Immunological parameters associated with vitiligo treatment: a literature review based on clinical studies
A C G Abreu, G G Duarte, J Y P Miranda, D G Ramos et al
Autoimmune Disease 2015, Article ID 196537, 5 pages
https://www.hindawi.com/journals/ad/2015/196537/
■ Translation, cross-cultural adaptation and validation of the vitiligo-specifi c health-related quality of life instrument (VitiQoL) into Brazilian Portuguese.
Boza, Juliana Catucci et al.
An. bras. dermatol., June 2015, vol.90, no.3, p.358-362
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962015000300358&lng=en&nrm=iso
■ Oxidative stress and immune system in vitiligo and thryroid diseases
Roberta Colucci, Federica Dragoni, Silvia Moretti
Oxid Med Cell Longev. 2015; 2015: 631927
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370195/
■ Epidermal curettage technique (ECT) for tissue harvest from the donor area for melanocyte autologous grafting in cases of vitiligo
Machado Filho, Carlos D’ Apparecida Santos and Timoner, Fabio Roismann
An. bras. dermatol., July 2014, vol.89, no.4, p.681-683
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000400681&lng=en&nrm=iso
■ Survey and online discussion groups to develop a patient-rated outcome measure on acceptability of treatment response in vitiligo
Selina K Tour, Kim S Thomas, Dawn-Marie Walker et al
BMC Dermatol. 2014; 14: 10
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075774/
■ Vitiligo – Part 1.
Tarlé, Roberto Gomes et al.
An. Bras. Dermatol., June 2014, vol.89, no.3, p.461-470
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000300461&lng=en&nrm=iso
■ Vitiligo – Part 2 – classification, histopathology and treatment.
Faria, Adriane Reichert et al.
An. bras. dermatol., Sept 2014, vol.89, no.5, p.784-790
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000500784&lng=en&nrm=iso
■ Concise review of recent studies in vitiligo
Mohamed Allam, Hassan Riad
Qatar Med J. 2013; 2013(2): 1–19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080492/
■ Non-cultured melanocyte/keratinocyte transplantation for the treatment of stable vitiligo on the face: report of two cases
Ramos, Mariana Gontijo et al.
An. bras. dermatol., Oct 2013, vol.88, no.5, p.811-813
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962013000500811&lng=en&nrm=iso
■ Surgical intervations for vitiligo: na evidence-based review
S V Mulekar, P Isedeh,
British Journal of Dermatology 2013, vol 169 (3): 57-66
https://onlinelibrary.wiley.com/doi/10.1111/bjd.12532
■ Guidelines for the management of vitiligo: the European Dermatologu Forum consensus
A Taieb, A Alomar, M Böhm et AL
British Journal of Dermatology 2013, vol 168 (1): 5-19
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2133.2012.11197.x
■ Clinical epidemiological profile of vitiligo in children and adolescents
Marinho, Flauberto de Sousa, Cirino, Pablo Vitoriano and Fernandes, Nurimar C.
An. bras. dermatol., Dec 2013, vol.88, no.6, p.1026-1028
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962013000601026&lng=en&nrm=iso&tlng=en
■ VIEWPOIN – Vitiligo and alopecia areata: Apples and oragnes?
John E. Harris
Exp Dermatol. 2013 Dec; 22(12): 10.1111/exd.1226
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867815/
■ Action of topical mometasone on the pigmented halos of micrografting in patients with vitiligo
Saldanha, Karine Dantas Diógenes, Machado Filho, Carlos D’Apparecida Santos and Paschoal, Francisco Macedo
An. Bras. Dermatol., Oct 2012, vol.87, no.5, p.685-69
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962012000500002&lng=en&nrm=iso&tlng=en
■ Pomada de tacrolimo 0,1% no tratamento de vitiligo: série de casos.
Tamler, Carla et al.
An. Bras. Dermatol., Fev 2011, vol.86, no.1, p.169-172
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962011000100034&lng=en&nrm=iso
■ Vitiligo y terapia con inmunoglobulina intravenosa: a propósito de un paciente con síndrome de Sjögren
Badilla P, Alejandro and Díaz G, Carolina
Rev. méd. Chile, Abr 2011, vol.139, no.4, p.484-48
https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872011000400011&lng=es&nrm=iso
■ Perfil epidemiológico dos pacientes com vitiligo e sua associação com doenças da tireóide
Nunes, Daniel Holthausen and Esser, Ligia Maria Hademann
An. Bras. Dermatol., Abr 2011, vol.86, no.2, p.241-248
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962011000200006&lng=en&nrm=iso
■ Vitiligo is na independent favourable prognosis factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study
P Quaglino, F Marenco, S Osella-Abate et AL
Annals of Oncology 2010, vol 21 (2): 409-414
https://academic.oup.com/annonc/article/21/2/409/326023
■ Factores psicobiológicos en vitiligo infantil: Posible rol en su génesis e impacto en la calidad de vida.
Schwartz, Rodrigo, Sepúlveda, Juan Enrique and Quintana, Teresa
Rev. méd. Chile, Ene 2009, vol.137, no.1, p.53-62
https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000100008&lng=es&nrm=iso
■ Guideline for the diagnosis and management of vitiligo
D J Gawkrodger, A D Ormerod L Shaw et al
British Journal of Dermatology 2008, vol 159 (5): 1051-1076
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2133.2008.08881.x
by Dr Paulo Fernando Leite
■ Cardiologia/Prevenção Cardiovascular
■ Estratificação de Risco Cardiovascular
Av Contorno 8351 – Conj 01
Belo Horizonte/MG/Brasil
Tel: 31 32919216 2917003 3357229
(- consulta particular –)
CRMMG: 7026
Email: pfleite1873@gmail.com